Analyzing SenesTech (SNES) & Its Peers

SenesTech (NASDAQ: SNES) is one of 191 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare SenesTech to similar companies based on the strength of its institutional ownership, risk, valuation, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of recent ratings for SenesTech and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SenesTech 0 0 2 0 3.00
SenesTech Competitors 708 2590 6916 146 2.63

SenesTech presently has a consensus price target of $8.50, indicating a potential upside of 1,207.49%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 19.82%. Given SenesTech’s stronger consensus rating and higher possible upside, equities research analysts plainly believe SenesTech is more favorable than its peers.


This table compares SenesTech and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SenesTech -14,473.40% -190.41% -150.12%
SenesTech Competitors -4,394.16% -464.87% -41.78%

Earnings and Valuation

This table compares SenesTech and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
SenesTech $320,000.00 -$10.79 million -0.49
SenesTech Competitors $227.13 million -$38.54 million -52.23

SenesTech’s peers have higher revenue, but lower earnings than SenesTech. SenesTech is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

15.3% of SenesTech shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 27.4% of SenesTech shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


SenesTech beats its peers on 7 of the 12 factors compared.

About SenesTech

SenesTech, Inc. is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes. Using bait stations, ContraPest is dispensed in a palatable liquid formulation that promotes sustained consumption by rodent communities. Its formulation causes both female and male rats to become infertile once they have consumed the dose. The active ingredient in females accelerates the rate at which ovarian follicles (egg structures) are depleted. Once these cells are gone, the animal cannot reproduce. In males, there is a marked reduction in the ability to fertilize eggs and, often complete sterility. ContraPest is designed, formulated and dispensed for handlers and non-target species, such as wildlife and pets in a biodegradable product.

Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with's FREE daily email newsletter.

Leave a Reply